Loading…
Partial Opioid Agonist·Addiction Medicine
Maintenance treatment for Opioid Use Disorder
No source link confirmed for this record yet. Its own source notes are under Additional.
Max Dose
32 mg/day
Half-life
24–42 h
Caution: Precip. W/D
RISK
Resp. Depression
CEILING
Avoid / Cautions
Contraindicated in severe respiratory insufficiency, severe hepatic impairment, and hypersensitivity. Moderate hepatic impairment may be inappropriate and needs cautious specialist review. Use caution in severe renal impairment, pregnancy, lactation, and with CNS depressants.
Overview
Buprenorphine/naloxone soluble film for opioid-dependence treatment within medical, social and psychological care. Buprenorphine provides partial mu-agonist activity; naloxone is included to reduce injection misuse.
Clinical Focus
Start only when withdrawal is established enough to reduce precipitated-withdrawal risk. Severe hepatic impairment is contraindicated; moderate hepatic impairment requires caution because naloxone exposure rises disproportionately.
Bottom Line
Useful OAT option with lower overdose risk than full agonists, but induction timing, hepatic function, CNS depressants, dental effects, and acute-pain planning need active management.
Brand Names
Suboxone
Oral Routes
Soluble films for sublingual or buccal administration. Supplied strengths include 2/0.5 mg and 8/2 mg in Australia; films are not designed to be split or swallowed whole.
Prescribing & PBS
S8. PBS search confirms Suboxone Film listings under the Section 100 Opioid Dependence Treatment Program (ODTP) for 2/0.5 mg and 8/2 mg films (transitioned from legacy S100 HSD Community Access post-July 2023); confirm current jurisdictional OAT authority and PBS restriction details before prescribing.
Primary
Maintenance treatment for Opioid Use Disorder.
Clinical Place
Safer than Methadone due to lower overdose risk and less QTc prolongation.
No calculator, monitoring schedule or factsheet is linked to this medicine page yet.